Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.60 0.65% 1,647.20 1,644.60 1,645.20 1,653.60 1,620.80 1,627.20 10,986,803 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.5 82,872

GlaxoSmithKline's Nucala Approved in Europe for Additional Diseases

17/11/2021 7:55am

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

From Oct 2021 to Jan 2022

Click Here for more Glaxosmithkline Charts.

By Sabela Ojea


GlaxoSmithKline PLC said Wednesday that its Nucala monoclonal antibody has been approved in Europe by the European Commission for three additional eosinophil-driven diseases.

The British pharma major said this antibody is the first approved targeted treatment for use in four of these eosinophil-driven conditions.

Eosinophil-driven diseases are inflammatory conditions linked to elevated levels of eosinophils, a type of white blood cell, the company said.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

November 17, 2021 02:40 ET (07:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220121 22:03:21